lutetium (177Lu) chloride

This medicine is authorised for use in the European Union.


ilLuzyce is a solution containing a radioactive form of lutetium (177lu) that is used for radiolabelling other medicines. Radiolabelling is a technique where a substance is labelled with a radioactive compound. Once the substance is radiolabelled with ilLuzyce, it then carries the radioactivity to where it is needed in the body (for example, the site of a tumour).

ilLuzyce is used to radiolabel medicines that have been specifically developed for use with lutetium (177lu) chloride.

ilLuzyce contains the active substance lutetium (177lu) chloride.

This EPAR was last updated on 21/09/2022

Authorisation details

Product details
Agency product number
Active substance
lutetium (177Lu) chloride
International non-proprietary name (INN) or common name
lutetium (177Lu) chloride
Therapeutic area (MeSH)
Radionuclide Imaging
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Billev Pharma Aps
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Slotsmarken 10
2970 Hoersholm

Product information

15/09/2022 Illuzyce - EMEA/H/C/005859 -

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Therapeutic radiopharmaceuticals

Therapeutic indication

ilLuzyce is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride.

Assessment history

How useful was this page?

Add your rating